Grégoire Marret

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Nicolas Delanoy, Jean‐Marie Michot, Thibault Comont et al. · The Lancet Haematology · 2018 · 292 citations

Pharmacy, Hematology, Immunology +16

Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial

Manuel Rodrigues, Giulia Vanoni, Pierre Loap et al. · Nature Communications · 2023 · 52 citations · Full text

Medicine, Immunology, Oncology +17

Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial

Marc Hilmi, Maud Kamal, Sophie Vacher et al. · European Journal of Cancer · 2023 · 40 citations · Full text

Life Sciences, Immunology, Oncology +17

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Réza‐Thierry Elaidi, A. Harbaoui, Benoit Beuselinck et al. · Annals of Oncology · 2014 · 30 citations · Full text

Medicine, Oncology, Pharmacology +12

Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery

Aurélie Moreira, A. Poulet, Julien Masliah‐Planchon et al. · ESMO Open · 2021 · 29 citations · Full text

Medicine, Oncology, Oral Pathology +17